B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.72B
AUM Growth
-$442M
Cap. Flow
-$1.85B
Cap. Flow %
-67.9%
Top 10 Hldgs %
40.29%
Holding
91
New
5
Increased
13
Reduced
23
Closed
19
Avg Time Held
0.7 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$71.4M
2
PEN icon
Penumbra
PEN
+$28.2M
3
TRML icon
Tourmaline Bio
TRML
+$18.1M
4
GPCR icon
Structure Therapeutics
GPCR
+$16.1M
5
LNTH icon
Lantheus
LNTH
+$14M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$61.5M
2
NTRA icon
Natera
NTRA
+$44.8M
3
MRUS icon
Merus
MRUS
+$35.7M
4
ISRG icon
Intuitive Surgical
ISRG
+$33.6M
5
GKOS icon
Glaukos
GKOS
+$30.9M

Sector Composition

Rank Sector Weight
1 Miscellaneous 51.4%
2 Healthcare 48.6%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
1
Neurocrine Biosciences
NBIX
$13.8B
$94.2M 3.46%
715,209
-252,815
-26% -$29.1M
2023 Q1
3 quarters
PCVX icon
2
Vaxcyte
PCVX
$10.6B
$81M 2.98%
1,289,965
-329,588
-20% -$17.1M
2022 Q4
4 quarters
XENE icon
3
Xenon Pharmaceuticals
XENE
$3.28B
$75.9M 2.79%
1,647,311
-456,085
-22% -$16.1M
2022 Q4
4 quarters
DAWN icon
4
DELISTED
Day One Biopharmaceuticals
DAWN
$61.5M 2.26%
4,215,573
+500,000
+13% +$6.06M
2022 Q4
4 quarters
IRTC icon
5
iRhythm Holdings
IRTC
$3.5B
$60.8M 2.23%
568,157
– –
2022 Q4
4 quarters
ARGX icon
6
argenx
ARGX
$51.5B
$58.3M 2.14%
+153,204
New +$71.4M
2023 Q4
0 quarters
PEN icon
7
Penumbra
PEN
$12.6B
$56M 2.06%
222,792
+127,477
+134% +$28.2M
2022 Q4
4 quarters
KROS icon
8
Keros Therapeutics
KROS
$219M
$44.5M 1.63%
1,118,961
-238,348
-18% -$7.47M
2023 Q2
2 quarters
FNA icon
9
DELISTED
Paragon 28, Inc.
FNA
$41.8M 1.53%
3,361,824
– –
2023 Q1
3 quarters
IMCR icon
10
Immunocore
IMCR
$1.46B
$41.8M 1.53%
611,365
-295,608
-33% -$15.4M
2023 Q1
3 quarters
TMO icon
11
Thermo Fisher Scientific
TMO
$249B
$40.2M 1.48%
75,749
– –
2023 Q2
2 quarters
ALGN icon
12
Align Technology
ALGN
$10.3B
$40.1M 1.47%
146,313
+21,100
+17% +$5M
2022 Q4
4 quarters
NVRO icon
13
DELISTED
NEVRO CORP.
NVRO
$38.2M 1.4%
1,776,368
– –
2022 Q4
4 quarters
INSP icon
14
Inspire Medical Systems
INSP
$1.97B
$37.6M 1.38%
184,658
+84,358
+84% +$13.7M
2023 Q3
1 quarter
KIDS icon
15
OrthoPediatrics
KIDS
$581M
$36M 1.32%
1,107,770
+50,000
+5% +$1.45M
2022 Q4
4 quarters
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.06B
$34.3M 1.26%
5,718,477
+355,497
+7% +$2.06M
2023 Q1
3 quarters
LEGN icon
17
Legend Biotech
LEGN
$3.7B
$33.9M 1.24%
562,600
-316,964
-36% -$20.1M
2022 Q4
4 quarters
MRVI icon
18
Maravai LifeSciences
MRVI
$976M
$33M 1.21%
5,040,635
+1,065,778
+27% +$6.89M
2023 Q2
2 quarters
LNTH icon
19
Lantheus
LNTH
$6.53B
$30.7M 1.13%
495,100
+206,800
+72% +$14M
2023 Q3
1 quarter
ALEC icon
20
Alector
ALEC
$210M
$26.5M 0.97%
3,324,308
-749,812
-18% -$4.44M
2022 Q4
4 quarters
KRYS icon
21
Krystal Biotech
KRYS
$9.79B
$24.3M 0.89%
196,200
+118,703
+153% +$13.2M
2022 Q4
4 quarters
TRML icon
22
DELISTED
Tourmaline Bio
TRML
$23.7M 0.87%
+906,820
New +$18.1M
2023 Q4
0 quarters
GH icon
23
Guardant Health
GH
$21.9B
$20.5M 0.75%
758,928
+69,928
+10% +$1.83M
2023 Q2
2 quarters
GKOS icon
24
Glaukos
GKOS
$9.9B
$19.3M 0.71%
242,760
-453,032
-65% -$30.9M
2022 Q4
4 quarters
APGE icon
25
DELISTED
Apogee Therapeutics
APGE
$19M 0.7%
681,101
+189,988
+39% +$3.81M
2023 Q3
1 quarter
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q4 2023 Portfolio in Review

As of Q4 2023, Braidwell held 91 positions worth $2.72B, down 14% from $3.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Braidwell withdrew a net $1.85B in Q4 2023, closing 19 positions and reducing 23 holdings. Its most notable exit was Boston Scientific, an estimated $61.5M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 51% of assets, up from 48% a quarter earlier, followed by Healthcare and Consumer Staples.

Against the trend, Braidwell opened a new position in argenx worth $58.3M.

  • Braidwell's largest Q4 2023 buy was argenx: 153,204 shares worth $58.3M.
  • Braidwell added most to Penumbra in Q4 2023, an estimated $28.2M increase.
  • Braidwell's biggest Q4 2023 reduction was Merus, cutting an estimated $35.7M.
  • Braidwell fully exited Boston Scientific in Q4 2023, selling an estimated $61.5M.
  • Braidwell's ten largest holdings make up 40% of its $2.72B portfolio in Q4 2023.
  • Braidwell opened 5 new positions and closed 19 in Q4 2023.
  • Braidwell's portfolio value fell 14% quarter-over-quarter to $2.72B.

Based on Braidwell's 13F filing for Q4 2023, filed 14 Feb 2024.